Abstract: SA-PO032
Anemia at One Year After Kidney Transplantation Is a Risk Factor of Graft and Patient Survival
Session Information
- Transplantation: Clinical Outcomes
October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 1802 Transplantation: Clinical
Author
- El Agroudy, Amgad E., College of Medicine and Medical Sciences, Arabian Gulf University, Manama, capital, Bahrain
Background
Post-transplant anemia is multifactorial and highly prevalent. The purpose of this study was to assess whether the presence of anemia at 12 months year is an independent risk factor of mortality and graft survival.
Methods
All patients followed-up at a single center who survived at least 1 year after transplantation and
with serum creatinine ≤140 µmol/l (n = 297) were included. Demographic and clinical data were collected at baseline and at 1 year. Patients were divided into two groups (anemic and nonanemic) based on the presence of anemia (hemoglobin; 13 g/dl in men and 12 g/dl in women) at 12 months.
Results
Baseline characteristics such as age, gender, type of donor, etiology of end-stage kidney disease, pre-emptive transplant, duration of pre-transplant dialysis, type of primary immunosuppression and mismatches were similar in both groups. There was statistically higher use of induction therapy (p=0.021), rate of acute rejection after the first year (p=0.020), CMV infection (p=0.015) and chronic allograft damage (p=0.004) in anemic group compared to nonanemic group. Creatinine clearance at last follow-up was significantly lower in anemic (59.3 ± 10.8 ml/min) and nonanemic groups (45.3 ± 12.5 ml/mim) (P = 0.039). A Kaplan–Meier survival analysis at 10-year post-transplant showed significantly poorer death-censored graft survival in the anemic group, P = 0.04 and patient survival (p=0.03). There was more statistically rate of death with function graft in anemic group (p=0.043).
Conclusion
In this study, anemia at 1 year was independently associated with death-censored graft and patient survival. Anemic patients have higher rate of acute rejection, and chronic allograft damage.